EROAD (NZSE:ERD) Is Down 31.9% After Major North America Exit and Asset Impairment Pivot

  • Earlier today, EROAD announced a significant downgrade of its FY 2026 revenue guidance, the recognition of up to NZ$150 million in impairments on its North American intangible assets, and a renewed focus on its Australia and New Zealand operations, following the loss of a key North American customer.
  • This pivot comes as governments in the region move to expand road user charges to cover electric vehicles, creating new opportunities within EROAD's core markets.
  • We'll now examine how EROAD's shift away from North America and renewed ANZ focus impacts its longer-term investment story.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Advertisement

What Is EROAD's Investment Narrative?

For EROAD, the big picture now looks more complex. Investors must be comfortable with a company shifting gears quickly, moving its center of gravity back to Australia and New Zealand after major setbacks in North America, including the loss of a substantial customer and a NZ$150 million asset impairment. The sell-off in EROAD shares reflects how material these developments are: short-term catalysts like policy reform on electric vehicle road user charges in New Zealand and possibly Australia still matter, but growth expectations and risk profiles have changed. Where previous analysis flagged upside from regional technology partnerships and new product launches, the sudden revision to guidance and recurring revenue exposes more immediate execution risk in new markets, as well as questions about how quickly EROAD can replace lost North American momentum with domestic gains. If confidence in the company’s ability to capture new opportunities wavers, the share price may remain volatile as investors reassess fair value and future prospects.

But against the backdrop of local opportunities, customer concentration risk remains a key factor for the near term.

Despite retreating, EROAD's shares might still be trading 43% above their fair value. Discover the potential downside here.

Exploring Other Perspectives

NZSE:ERD Community Fair Values as at Oct 2025
NZSE:ERD Community Fair Values as at Oct 2025
The Simply Wall St Community has posted seven individual fair value estimates for EROAD, stretching from NZ$1.20 up to NZ$4.96 per share. While some see significant upside, recent news about impaired assets and reduced guidance has sharpened debate on future earnings and growth potential. Explore how these diverging opinions could reflect on EROAD’s path forward.

Explore 7 other fair value estimates on EROAD - why the stock might be worth 36% less than the current price!

Build Your Own EROAD Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if EROAD might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NZSE:ERD

EROAD

Provides electronic on-board units and software as a service to the transport industry in New Zealand, the United States, and Australia.

Adequate balance sheet and slightly overvalued.

Similar Companies

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1155.3% undervalued
51 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
IREN logo
BlackGoat on IREN ·

IREN's Bold Moves in Sustainable Bitcoin Mining & AI Data Centers

Fair Value:US$71.4849.2% undervalued
204 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
HE
HedgeY
ARM logo
HedgeY on Arm Holdings ·

The Architecture Layer of AI Computing - But Priced Like the Future Already Arrived?

Fair Value:US$43038.1% undervalued
9 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative
HI
Hidden_Rock_Capital
FISV logo
Hidden_Rock_Capital on Fiserv ·

Temporary "perfect storm" leads to opportunity to buy financial services leader for less than 5x long-term earnings

Fair Value:US$119.9956.4% undervalued
13 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

NE
AIIO logo
newsfinder11221 on Robo.ai ·

Robo.ai (NASDAQ: AIIO): Building the Infrastructure Behind the AI Revolution

Fair Value:US$540.4% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
ALMIN logo
European_Hidden_Gem_Stocks on MINT Société anonyme ·

Mint SA: A French Micro-Cap Energy Retailer Worth Watching

Fair Value:€1153.1% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kaspertidemann
BARDJU logo
kaspertidemann on BAR DJUS ·

The Best Season Is Still Ahead

Fair Value:DKK 4.120.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.917.3% undervalued
87 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28029.8% undervalued
195 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.7% undervalued
73 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0